104 related articles for article (PubMed ID: 7867681)
1. Pharmacokinetic and pharmacodynamic studies following single and multiple doses of rolafagrel, a novel inhibitor of thromboxane synthase, in normal volunteers.
Gatti G; Bartoli A; Bertin D; Strolin-Benedetti M; Perucca E
Eur J Clin Pharmacol; 1994; 47(3):275-80. PubMed ID: 7867681
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics and pharmacodynamics of a new thromboxane synthetase inhibitor, 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (DP-1904), in man after single oral administration.
Tanaka M; Ono K; Takegoshi T; Shiozawa T; Suzuki T; Nii S; Shibata H
J Pharm Pharmacol; 1989 Oct; 41(10):680-4. PubMed ID: 2575144
[TBL] [Abstract][Full Text] [Related]
3. A phase I dose-ranging safety and pharmacokinetics study of a novel oral thromboxane synthase inhibitor, FCE 22, 178.
Li RC; Narang PK; Lewis RC; Hatfield NZ; Rossi DT; Colborn DC
J Clin Pharmacol; 1993 Apr; 33(4):373-80. PubMed ID: 8473553
[TBL] [Abstract][Full Text] [Related]
4. Multiple dose trial of the thromboxane synthase inhibitor furegrelate in normal subjects.
Mohrland JS; Vander Lugt JT; Lakings DB
Eur J Clin Pharmacol; 1990; 38(5):485-8. PubMed ID: 2379533
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers.
Uematsu T; Kosuge K; Umemura K; Nakano M; Terakawa M; Nakashima M
J Pharm Pharmacol; 1996 Apr; 48(4):380-5. PubMed ID: 8794987
[TBL] [Abstract][Full Text] [Related]
6. Disposition and effect of the new thromboxane synthetase inhibitor 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid in man.
Tanaka M; Ono K; Hakusui H; Takegoshi T; Shiozawa T; Nii S; Shibata H
Arzneimittelforschung; 1990 Jun; 40(6):712-5. PubMed ID: 2397009
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic profiles of CS-518, a selective, long-lasting thromboxane synthase inhibitor, after single and multiple oral administration to healthy volunteers.
Uematsu T; Nagashima S; Inaba H; Mizuno A; Kosuge K; Nakashima M
J Clin Pharmacol; 1994 Jan; 34(1):41-7. PubMed ID: 8132850
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic modelling of DP-1904, a novel thromboxane synthetase inhibitor in rabbits, based on an indirect response model.
Zheng NX; Sato H; Adachi I; Horikoshi I
Eur J Drug Metab Pharmacokinet; 1996; 21(4):285-93. PubMed ID: 9074892
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics and pharmacodynamics of a new thromboxane synthetase inhibitor, 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (DP-1904) in man after repeated oral doses.
Tanaka M; Ono K; Hakusui H; Takegoshi T; Shiozawa T; Suzuki T; Nii S; Shibata H
J Pharm Pharmacol; 1990 Jul; 42(7):491-5. PubMed ID: 1980290
[TBL] [Abstract][Full Text] [Related]
10. Administration to man of UK-37,248-01, a selective inhibitor of thromboxane synthetase.
Tyler HM; Saxton CA; Parry MJ
Lancet; 1981 Mar; 1(8221):629-32. PubMed ID: 6110861
[TBL] [Abstract][Full Text] [Related]
11. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
[TBL] [Abstract][Full Text] [Related]
12. Selective and nonselective inhibition of thromboxane formation.
FitzGerald GA; Oates JA
Clin Pharmacol Ther; 1984 May; 35(5):633-40. PubMed ID: 6370554
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of CGS 12970 and inhibition of thromboxane synthesis after oral administration in healthy adults.
Martin LL; Schaffer AV; Piraino A; Linberg L; Singh K; Rakhit A; Douglas FL
Clin Pharmacol Ther; 1991 Apr; 49(4):433-41. PubMed ID: 2015733
[TBL] [Abstract][Full Text] [Related]
15. Sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate (U-63557A), a new, selective thromboxane synthase inhibitor: intravenous and oral pharmacokinetics in dogs and correlations with ex situ thromboxane B2 production.
Wynalda MA; Liggett WF; Fitzpatrick FA
Prostaglandins; 1983 Aug; 26(2):311-24. PubMed ID: 6685888
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of Y-20811, a new long-acting thromboxane synthetase inhibitor by intravenous administration.
Kanamaru M; Nakashima M
J Clin Pharmacol; 1989 Jun; 29(6):563-7. PubMed ID: 2502563
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients.
Chouinard ML; Martin LL; Coffman T; Hamilton BH; Linberg LF; Pamidi A; Simke JP; Rakhit A
Clin Pharmacol Ther; 1992 Dec; 52(6):597-604. PubMed ID: 1458769
[TBL] [Abstract][Full Text] [Related]
19. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
